Dysregulated DDIT4 expression is seen in various cancers and its role in tumorigenesis is likely tumour‐dependent, based on previous studies.17, 18, 19 In breast cancer, DDIT4 is a tumour suppressor against miR‐495‐mediated oncogenesis and hypoxia resistance.20 In ovarian cancer, on the other hand, it is positively correlated with the oncogene p‐AKT and predicts late FIGO stage and serous adenocarcinoma,13 indicating its role as a tumour promotor. The gene discussed is DDIT4; the disease is breast carcinoma.